Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03760068 · ClinicalTrials.gov registry record · Phase 3
Mylan Insulin Aspart Study
A Phase 3 study of Diabetes Mellitus, Type 1, sponsored by Mylan.
- Completed
- Registry status
- Phase 3
- Development phase
- 478
- Enrollment target
- 20
- Study locations
NCT03760068 is a Phase 3 study of Diabetes Mellitus, Type 1 that has completed, run by Mylan. The registered enrollment target is 478 participants, below the 1,262-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT03760068, a Phase 3 study of Diabetes Mellitus, Type 1, has completed, sponsored by Mylan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 478 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of this phase III trial is to demonstrate the equivalence in the safety and efficacy profile between MYL-1601D and NovoLog® in patients with T1DM.
Conditions Studied
Interventions
- DRUG MYL-1601D Product
- DRUG FlexPen NovoLog®
Study Locations (20)
California
- John Muir Physician Network - Concord
- Valley Research - Fresno
- Marin Endocrine Care & Research, Inc. - Greenbrae
- Diabetes/Lipid Management and Research Center - Huntington Beach
- Diabetes And Endocrine Associates - La Mesa
- Long Beach Center For Clinical Research - Long Beach
- Office of Richard S. Cherlin, M.D - Los Gatos
- The Rose Salter Medical Research Foundation - Newport Beach
- Providence Clinical Research - North Hollywood
- California Medical Research Associates Inc - Northridge
- Pacific Reserach Partners - Oakland
- Palmtree Clinical Research, Inc. - Palm Springs
- Western Univ of Health Science - Pomona
- Mills-Peninsula Health Services Diabetes Research Institute - San Mateo
- NorCal Endocrinology and Internal Medicine - San Ramon
- Sansum Diabetes Research Institute - Santa Barbara
Arizona
- Phoenician Centers for Research - Phoenix
- Precision Trials - Phoenix
Alabama
- Endocrinology Associates Montgomery - Montgomery
Arkansas
- Medical Investigations Inc. - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 478 participants |
| Start Date | 2018-11-07 |
| Est. Completion | 2020-01-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03760068
The ClinicalTrials.gov registry entry for NCT03760068 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 478 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,262-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (62% lower). The listed sponsor is Mylan, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 2 interventions - of which MYL-1601D Product is the first listed.
NCT03760068 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT03760068 about?
NCT03760068 is a clinical study titled "Mylan Insulin Aspart Study". The aim of this phase III trial is to demonstrate the equivalence in the safety and efficacy profile between MYL-1601D and NovoLog® in patients with T1DM.
What is the current status of trial NCT03760068?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 478 participants. The study started on 2018-11-07. Estimated completion is 2020-01-17.
What conditions does trial NCT03760068 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT03760068?
The interventions under investigation include: MYL-1601D Product (DRUG), FlexPen NovoLog® (DRUG).
Who is sponsoring clinical trial NCT03760068?
This trial is sponsored by Mylan, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03760068 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
RECRUITING · Phase 3
-
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
RECRUITING · Phase 3
-
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
RECRUITING · Phase 3
-
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
RECRUITING · Phase 3
-
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
RECRUITING · Phase 3
-
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.